| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery ☆
|
Pautier, P.
|
|
|
6 |
4 |
p.
|
artikel
|
| 2 |
Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study
|
van Walle, L.
|
|
|
6 |
4 |
p.
|
artikel
|
| 3 |
Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study
|
Zheng, X.
|
|
|
6 |
4 |
p.
|
artikel
|
| 4 |
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
|
Eriksson, M.
|
|
|
6 |
4 |
p.
|
artikel
|
| 5 |
Cancer and hepatic steatosis
|
Paternostro, R.
|
|
|
6 |
4 |
p.
|
artikel
|
| 6 |
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines ☆
|
Crawford, G.B.
|
|
|
6 |
4 |
p.
|
artikel
|
| 7 |
Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores
|
Broekman, K.E.
|
|
|
6 |
4 |
p.
|
artikel
|
| 8 |
Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis
|
Hibino, Y.
|
|
|
6 |
4 |
p.
|
artikel
|
| 9 |
Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival
|
Fan, Y.
|
|
|
6 |
4 |
p.
|
artikel
|
| 10 |
Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy
|
Delombaerde, D.
|
|
|
6 |
4 |
p.
|
artikel
|
| 11 |
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)
|
Conforti, F.
|
|
|
6 |
4 |
p.
|
artikel
|
| 12 |
Corrigendum to ‘COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)’
|
Bianchi, F.
|
|
|
6 |
4 |
p.
|
artikel
|
| 13 |
Corrigendum to ‘Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients’
|
Richter, R.
|
|
|
6 |
4 |
p.
|
artikel
|
| 14 |
Corrigendum to ‘Remembering Professor José Baselga’
|
Tabernero, J.
|
|
|
6 |
4 |
p.
|
artikel
|
| 15 |
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
|
Pichler, M.
|
|
|
6 |
4 |
p.
|
artikel
|
| 16 |
Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis
|
Peacock, H.M.
|
|
|
6 |
4 |
p.
|
artikel
|
| 17 |
Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
|
De Cock, L.
|
|
|
6 |
4 |
p.
|
artikel
|
| 18 |
Editorial Board
|
|
|
|
6 |
4 |
p.
|
artikel
|
| 19 |
Emerging targets for anticancer vaccination: IDH
|
Platten, M.
|
|
|
6 |
4 |
p.
|
artikel
|
| 20 |
Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’
|
Choueiri, T.K.
|
|
|
6 |
4 |
p.
|
artikel
|
| 21 |
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
|
Filipits, M.
|
|
|
6 |
4 |
p.
|
artikel
|
| 22 |
European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN
|
Blay, J.-Y.
|
|
|
6 |
4 |
p.
|
artikel
|
| 23 |
Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
|
Hotta, K.
|
|
|
6 |
4 |
p.
|
artikel
|
| 24 |
How I treat stage II colon cancer patients
|
Taieb, J.
|
|
|
6 |
4 |
p.
|
artikel
|
| 25 |
How we treat medulloblastoma in adults
|
Franceschi, E.
|
|
|
6 |
4 |
p.
|
artikel
|
| 26 |
How we treat primary central nervous system lymphoma
|
Calimeri, T.
|
|
|
6 |
4 |
p.
|
artikel
|
| 27 |
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
|
Rapposelli, I.G.
|
|
|
6 |
4 |
p.
|
artikel
|
| 28 |
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)
|
Jiménez-Labaig, P.
|
|
|
6 |
4 |
p.
|
artikel
|
| 29 |
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge
|
Bono, M.
|
|
|
6 |
4 |
p.
|
artikel
|
| 30 |
Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
|
Kato, K.
|
|
|
6 |
4 |
p.
|
artikel
|
| 31 |
Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies
|
Xiao, Y.
|
|
|
6 |
4 |
p.
|
artikel
|
| 32 |
Intratumor morphologic and transcriptomic heterogeneity in V600E BRAF-mutated metastatic colorectal adenocarcinomas
|
Angerilli, V.
|
|
|
6 |
4 |
p.
|
artikel
|
| 33 |
Management of lung cancer patients' quality of life in clinical practice: a Delphi study
|
Westeel, V.
|
|
|
6 |
4 |
p.
|
artikel
|
| 34 |
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)
|
Dano, D.
|
|
|
6 |
4 |
p.
|
artikel
|
| 35 |
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review
|
Solares, I.
|
|
|
6 |
4 |
p.
|
artikel
|
| 36 |
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study) ☆
|
Perez-Fidalgo, J.A.
|
|
|
6 |
4 |
p.
|
artikel
|
| 37 |
Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines
|
Resch, I.
|
|
|
6 |
4 |
p.
|
artikel
|
| 38 |
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials
|
Severi, S.
|
|
|
6 |
4 |
p.
|
artikel
|
| 39 |
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
|
Subbiah, V.
|
|
|
6 |
4 |
p.
|
artikel
|
| 40 |
Prognostic impact of six versus eight cycles of standard regimen in patients with diffuse large B-cell lymphoma: propensity score-matching analysis
|
Oiwa, K.
|
|
|
6 |
4 |
p.
|
artikel
|
| 41 |
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery
|
Moreira, A.
|
|
|
6 |
4 |
p.
|
artikel
|
| 42 |
Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
|
Van Cutsem, E.
|
|
|
6 |
4 |
p.
|
artikel
|
| 43 |
Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study
|
Davie, A.
|
|
|
6 |
4 |
p.
|
artikel
|
| 44 |
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
|
Adams, E.
|
|
|
6 |
4 |
p.
|
artikel
|
| 45 |
Skip pattern approach toward the early access of innovative anticancer drugs
|
Apolone, G.
|
|
|
6 |
4 |
p.
|
artikel
|
| 46 |
Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations
|
Astaras, C.
|
|
|
6 |
4 |
p.
|
artikel
|
| 47 |
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study
|
Nannini, M.
|
|
|
6 |
4 |
p.
|
artikel
|
| 48 |
SUNRISE-DI study. The daily sunrise is easier to predict than the benefit of adjuvant treatment in colon cancer
|
Carmona-Bayonas, A.
|
|
|
6 |
4 |
p.
|
artikel
|
| 49 |
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature
|
Heregger, R.
|
|
|
6 |
4 |
p.
|
artikel
|
| 50 |
Table of Contents
|
|
|
|
6 |
4 |
p.
|
artikel
|
| 51 |
The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II
|
Lim, K.H.J.
|
|
|
6 |
4 |
p.
|
artikel
|
| 52 |
Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)
|
Uutela, A.
|
|
|
6 |
4 |
p.
|
artikel
|
| 53 |
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study
|
Tabernero, J.
|
|
|
6 |
4 |
p.
|
artikel
|
Tijdschrift beschrijving